This is featured post 1 title
Replace these every slider sentences with your featured post descriptions.Go to Blogger edit html and find these sentences.Now replace these with your own descriptions.This theme is Bloggerized by Lasantha - Premiumbloggertemplates.com.
This is featured post 2 title
Replace these every slider sentences with your featured post descriptions.Go to Blogger edit html and find these sentences.Now replace these with your own descriptions.This theme is Bloggerized by Lasantha - Premiumbloggertemplates.com.
This is featured post 3 title
Replace these every slider sentences with your featured post descriptions.Go to Blogger edit html and find these sentences.Now replace these with your own descriptions.This theme is Bloggerized by Lasantha - Premiumbloggertemplates.com.
Showing posts with label Elder care. Show all posts
Showing posts with label Elder care. Show all posts
Tuesday, February 2, 2010
Call to end exclusion of elderly from drug trials
This news story caught my eye because I have become concerned about this very issue over the past six or seven years. In my way of thinking it is important to set up specific drug trials not just for Elders but for children and women too.
In 2003 my mother suffered a closed head injury, and as a result of her fall and the TBI she developed expressive aphasia.
Expressive aphasia is condition and an acquired disorder of language due to brain damage. Most aphasias and related disorders are due to stroke, head injury, cerebral tumors, or degenerative diseases. People may lose the ability to produce speech, to comprehend speech, to repeat, and to hear and read words in many nuanced ways. Language difficulties can also be affected by pharmaceutical drugs often over used in faculties that care for Elders.
Speech and language therapy is the mainstay of care for people with with aphasia. The timing and nature of the interventions for aphasia vary widely. Blinded studies are limited, and recovery of many degrees is expected. Studies also indicate that speech and language therapy does improve clinical outcomes in aphasia, but individualized programs are important.
The potential for functional recovery from primarily expressive aphasia after stroke is excellent. A neurologist should be key in evaluation and care, as well as speech therapy.
After her injury, my mother was placed in a 5 Star facility in Naples, Florida. She was loaded up with an over abundance of psychotropic drugs, including Zyprexa, yet did not have a neurologist or speech therapy prescribed.
Zyprexa is questionable for the elderly, especially for use in elderly women, and it can precipitate diabetes. The case in point is that regardless of the number of drugs prescribed, and failure of the center to evaluate the drugs for interaction, no one except me questioned the use of this drug in my mother's care. Zyprexa has an unusually difficult time being excreted by older women and as a result has a longer half-life.
Another drug being given to my mother, not prescribed by a neurologist, was Neurontin, and it is implicated in the development of impaired speech. And yet another one of the several SSRIs perscribed has a known side effect of suicidal thinking. My mother tried to jump out of a window. The outcome: more drugs to sedate her further.
The house psychiatrist diagnosed my mother as depressed. Yet when I asked how he diagnosed her with the aphasia, he could not answer. He just prescribed more drugs.
I contacted a colleague in the pharmaceutical research section dealing with psychotropic durgs at the FDA for an opinion on the list of drugs prescribed to my mother. He was shocked, and especially noted the severe issues indicated by the drug interaction profile.
The care center supplying pharmacy never conducted a thorough interaction profile.
The attending GP, a whining DO from a near by town, most likely interested in the Medicare reimbursement more than my mother's condition, whined to my brother after I talked with him, saying he did not like the questions I was asking.
The director of nursing threatened forced relocation if my mother was taken off any of the drugs. Since the bill went to Medicare I am sure reimbursement was more the concern than my mother's well being. And of course there is the issue of staff convenience.
Well, my mother died last summer. She won't be forced now to take any more drugs, but for six years which must have been agonizing for her, she was over drugged and could not communicate.
My little brother, who held POA, a player in the insurance/finance business, made absolutely no effort to see that my mother was taken to a nationally recognized neurologist in Naples. Nor would acknowledge my concerns over the drugs and her treatment. He failed to get her even the most clearly established care for the aphasia, but was concerned over the cost of the drugs.
He also failed to tell the care center that my mother had a daughter, and didn't make any effort to contact me about this incident until three months after it happened.
Read the complete areticle here - http://news.bbc.co.uk/2/hi/health/8487509.stm
Wednesday, December 23, 2009
Too many Drugs, Too High Doses: Too Much for Elders
My mother was an Elder. She was over-drugged for a number of years in a Florida Five-Star facility and the threat of forced relocation was held over her POA if she wasn't drugged. I'm sure Medicare fraud is an issue here but needless to say, she was not alone.
I'm also wondering why doctors can't look at magnesium and B complex before drugs for hypertension, or even other natural approaches.
I'm also wondering why doctors can't look at magnesium and B complex before drugs for hypertension, or even other natural approaches.
Old heart patients 'over-drugged'
Elderly patients are being treated too aggressively for high blood pressure, researchers claim.
They say the "oldest olds", meaning patients aged 80 plus, are being given too many drugs and in too large doses, which may do them more harm than good.
The Cochrane scientists who looked at the available data say doctors can set their targets lower for octogenarians. This makes good economic and clinical sense given the expanding elderly population, they told bmj.com.
But doctors said high blood pressure is largely under-recognised and under-treated in the UK.
Growing need
Experts say the "oldest olds" are the fastest growing sector of the world's population.
According to latest estimates, the UK population of 85-year-olds will go up by a third by 2020.
And more than half of these will need treatment for high blood pressure, the British Medical Journal reports.“ Most sensible GPs - which most GPs are - take a pretty cautious view to doling out drugs to old people. ” Professor Peter Weissberg British Heart FoundationBut head of the Cochrane research group, Dr James Wright, says clinicians should change what they are presently doing and move towards a more conservative approach for the over 80s.
"I have done so with my patients," he said.
'Less better'
His review of existing studies, including data from two new trials which looked specifically at the effect of blood pressure drugs in this age group, found little evidence that aggressive treatment saves more lives.
Although fewer patients died of strokes, the total number of deaths from all causes was unchanged.
The only trial that found a significant reduction in overall mortality was the most conservative in terms of number of drugs and dose of drugs allowed.
Based on the findings, he suggests a target blood pressure of 150/80 mmHg is more sensible, and says doctors should not be worried if only half of their most elderly patients achieve it.
Professor Peter Weissberg, of the British Heart Foundation, said: "Most sensible GPs - which most GPs are - take a pretty cautious view to doling out drugs to old people.
"Hypertension is still largely under-treated. By and large, in the UK population, half of people with high blood pressure are not identified."
Story from BBC NEWS: http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/8426199.stm
Published: 2009/12/23 © BBC MMIX
Saturday, January 10, 2009
Alzheimer's drugs double death risk
Use of Fluoride containing anti-psychotics included in this study. Another issue to consider above most for problems with Alzheimer's disease.
Fluoride suppresses proper function of the thyroid gland. As I have mentioned elsewhere, 67% of people in Alzheimer's care facilities in 1998 had a thyroid disorder. Anyone on long term use of a fluoride containing drug, in an area where fluoride is forced into the municipal water system, is already on fluoride overload.
I guess I wonder where are those asking the right questions...
The Lancet Neurology, Early Online Publication, 9 January 2009
doi:10.1016/S1474-4422(08)70295-3
Longterm Risk of Death for Alzheimer's and Use of Antipsychotics
Editors' note: Antipsychotics do not improve cognitive or neuropsychiatric outcomes in most patients with dementia, and serious concerns have been raised about their side effects in the very old. Increased mortality rate and risk of cerebrovascular events have been reported by previous studies of relatively short duration (usually 12 weeks). In this article, the DART-AD investigators report long-term mortality rates among patients with Alzheimer's disease in residential care after 12-months of neuroleptic treatment, adding to the growing evidence against the use of antipsychotics in this vulnerable population.
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
Original Text: Clive Ballard MD a , Maria Luisa Hanney PhD b, Megan Theodoulou MRCPsych c, Simon Douglas BSc d, Rupert McShane MRCPsych e, Katja Kossakowski BSc a, Randeep Gill MBBS a, Edmund Juszczak MSc f, Ly-Mee Yu MSc f, Robin Jacoby DM c, for the DART-AD investigators
Background: Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer's disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.
Methods: Between October, 2001, and December, 2004, patients with AD who resided in care facilities in the UK were enrolled into a randomised, placebo-controlled, parallel, two-group treatment discontinuation trial. Participants were randomly assigned to continue with their antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months or to switch their medication to an oral placebo. The primary outcome was mortality at 12 months. An additional follow-up telephone assessment was done to establish whether each participant was still alive 24 months after the enrolment of the last participant (range 24—54 months). Causes of death were obtained from death certificates. Analysis was by intention to treat (ITT) and modified intention to treat (mITT).
This trial is registered with the Cochrane Central Registry of Controlled Trials/National Research Register, number ISRCTN33368770.
Findings: 165 patients were randomised (83 to continue antipsychotic treatment and 82 to placebo), of whom 128 (78%) started treatment (64 continued with their treatment and 64 received placebo). There was a reduction in survival in the patients who continued to receive antipsychotics compared with those who received placebo. Cumulative probability of survival during the 12 months was 70% (95% CI 58—80%) in the continue treatment group versus 77% (64—85%) in the placebo group for the mITT population. Kaplan—Meier estimates of mortality for the whole study period showed a significantly increased risk of mortality for patients who were allocated to continue antipsychotic treatment compared with those allocated to placebo (mITT log rank p=0·03; ITT p=0·02). The hazard ratio for the mITT group was 0·58 (95% CI 0·35 to 0·95) and 0·58 (0·36 to 0·92) for the ITT population. The more pronounced differences between groups during periods of follow up longer than 12 months were evident at specific timepoints (24-month survival 46% vs 71%; 36-month survival 30% vs 59%).
Interpretation: There is an increased long-term risk of mortality in patients with AD who are prescribed antipsychotic medication; these results further highlight the need to seek less harmful alternatives for the long-term treatment of neuropsychiatric symptoms in these patients.
Funding: UK Alzheimer's Research Trust.
Fluoride suppresses proper function of the thyroid gland. As I have mentioned elsewhere, 67% of people in Alzheimer's care facilities in 1998 had a thyroid disorder. Anyone on long term use of a fluoride containing drug, in an area where fluoride is forced into the municipal water system, is already on fluoride overload.
I guess I wonder where are those asking the right questions...
Alzheimer's drugs double death risk in elderly
By MARIA CHENG, AP Medical Writer
Thu Jan 8, 2009
LONDON – Anti-psychotic drugs commonly used to treat Alzheimer's disease may double a patient's chance of dying within a few years, suggests a new study that adds to concerns already known about such medications.
"For the vast majority of Alzheimer's patients, taking these drugs is probably not a worthwhile risk," said Clive Ballard, the paper's lead author, of the Wolfson Centre for Age-Related Diseases at King's College London.
"Would I want to take a drug that slightly reduced my aggression but doubled my risk of dying? I'm not sure I would," Ballard said.
The research was published Friday in the medical journal, Lancet Neurology.
Alzheimer's disease is the most common cause of dementia and causes symptoms including aggression, delusions and hallucinations. Previous studies have shown anti-psychotic drugs, which can help control the aggression and hallucinations for a few months raise the risk of death in older patients with dementia. There are other side effects, including respiratory problems and stroke.
Ballard and colleagues followed 165 patients aged 67 to 100 years with moderate to severe Alzheimer's disease from 2001 to 2004 in Britain. Half continued taking their anti-psychotic drugs, which included Risperdal, Thorazine and Stelazine. The other half got placebos.
Of the 83 receiving drugs, 39 were dead after a year. Of the 82 taking fake pills, 27 were dead after a year. Most deaths in both groups were due to pneumonia.
After two years, 46 percent of Alzheimer's patients taking the anti-psychotics were alive, versus 71 percent of those not on the drugs. After three years, only 30 percent of patients on the drugs were alive, versus 59 percent of those not taking drugs.
In the United Kingdom and the United States, guidelines advise doctors to use anti-psychotic drugs cautiously and temporarily. But in many nursing homes in Europe and North America, up to 60 percent of patients with dementia are routinely given the drugs for one to two years.
"The drug regimen for any person with Alzheimer's needs to be personalized," said William Thies of the Alzheimer's Association in the U.S. Thies was not connected to the study. "At some points, some people will be better off with no medication."
Simon Lovestone of the Institute of Psychiatry at King's College in London said psychiatrists should try environmental or behavioral therapies instead of anti-psychotics.
Experts aren't sure how the anti-psychotics increase patients' risk of dying. But they think the drugs could be damaging to the brain and their sedative effects make patients less able to exercise and more susceptible to deadly infections.
The study was paid for by the U.K. Alzheimer's Research Trust. Ballard reported receiving grants from various pharmaceutical companies which make drugs used to treat Alzheimer's patients.
___
On the Net: http://www.lancet.com
Copyright © 2009 The Associated Press. All rights reserved
The Lancet Neurology, Early Online Publication, 9 January 2009
doi:10.1016/S1474-4422(08)70295-3
Longterm Risk of Death for Alzheimer's and Use of Antipsychotics
Editors' note: Antipsychotics do not improve cognitive or neuropsychiatric outcomes in most patients with dementia, and serious concerns have been raised about their side effects in the very old. Increased mortality rate and risk of cerebrovascular events have been reported by previous studies of relatively short duration (usually 12 weeks). In this article, the DART-AD investigators report long-term mortality rates among patients with Alzheimer's disease in residential care after 12-months of neuroleptic treatment, adding to the growing evidence against the use of antipsychotics in this vulnerable population.
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
Original Text: Clive Ballard MD a , Maria Luisa Hanney PhD b, Megan Theodoulou MRCPsych c, Simon Douglas BSc d, Rupert McShane MRCPsych e, Katja Kossakowski BSc a, Randeep Gill MBBS a, Edmund Juszczak MSc f, Ly-Mee Yu MSc f, Robin Jacoby DM c, for the DART-AD investigators
Background: Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer's disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.
Methods: Between October, 2001, and December, 2004, patients with AD who resided in care facilities in the UK were enrolled into a randomised, placebo-controlled, parallel, two-group treatment discontinuation trial. Participants were randomly assigned to continue with their antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months or to switch their medication to an oral placebo. The primary outcome was mortality at 12 months. An additional follow-up telephone assessment was done to establish whether each participant was still alive 24 months after the enrolment of the last participant (range 24—54 months). Causes of death were obtained from death certificates. Analysis was by intention to treat (ITT) and modified intention to treat (mITT).
This trial is registered with the Cochrane Central Registry of Controlled Trials/National Research Register, number ISRCTN33368770.
Findings: 165 patients were randomised (83 to continue antipsychotic treatment and 82 to placebo), of whom 128 (78%) started treatment (64 continued with their treatment and 64 received placebo). There was a reduction in survival in the patients who continued to receive antipsychotics compared with those who received placebo. Cumulative probability of survival during the 12 months was 70% (95% CI 58—80%) in the continue treatment group versus 77% (64—85%) in the placebo group for the mITT population. Kaplan—Meier estimates of mortality for the whole study period showed a significantly increased risk of mortality for patients who were allocated to continue antipsychotic treatment compared with those allocated to placebo (mITT log rank p=0·03; ITT p=0·02). The hazard ratio for the mITT group was 0·58 (95% CI 0·35 to 0·95) and 0·58 (0·36 to 0·92) for the ITT population. The more pronounced differences between groups during periods of follow up longer than 12 months were evident at specific timepoints (24-month survival 46% vs 71%; 36-month survival 30% vs 59%).
Interpretation: There is an increased long-term risk of mortality in patients with AD who are prescribed antipsychotic medication; these results further highlight the need to seek less harmful alternatives for the long-term treatment of neuropsychiatric symptoms in these patients.
Funding: UK Alzheimer's Research Trust.
2:44 PM
ari sari
Posted in: 

